Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN Imprimir: 0893-9675
ISSN En Línea: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2018024859
pages 219-248

The Role of Tissue Factor in Cancer-Related Hypercoagulability, Tumor Growth, Angiogenesis and Metastasis and Future Therapeutic Strategies

Patrick Van Dreden
Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine, INSERM U938, Institut Universitaire de Cancérologie (IUC), Faculté de Médecine, Sorbonne Universities, Paris, France; Clinical Research Department, Diagnostica Stago, Gennevilliers, France
Ιsmail Εlalamy
Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine, INSERM U938, Institut Universitaire de Cancérologie (IUC), Faculté de Médecine, Sorbonne Universities, Paris, France; Service d'Hématologie Biologique Hôpital Tenon, Hôpitaux Universitaires Est Parisien, Assistance Publique Hôpitaux de Paris
Grigoris T. Gerotziafas
Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine, INSERM U938, Institut Universitaire de Cancérologie (IUC), Faculté de Médecine, Sorbonne Universities, Paris, France; Service d'Hématologie Biologique Hôpital Tenon, Hôpitaux Universitaires Est Parisien, Assistance Publique Hôpitaux de Paris

SINOPSIS

It is widely recognized that a strong correlation exists between cancer and aberrant hemostasis. Patients with various types of cancers often develop thrombosis, a phenomenon commonly referred to as Trousseau syndrome. Tissue factor (TF) is expressed by tumor cells and contributes to a variety of pathologic processes, such as thrombosis, tumor growth, tumor angiogenesis, and metastasis. Tissue factor is expressed in two naturally occurring protein isoforms: membrane-bound full-length TF (flTF) and soluble alternatively spliced TF (asTF). Tissue factor is the primary initiator of blood coagulation, and it triggers intracellular signaling through protease-activated receptors (PARs). PARs are activated either by TF/FVIIa complexes or by thrombin generated following coagulation activation. Furthermore, the noncoagulant asTF retains an integrin-binding site and stimulates angiogenesis by ligating endothelial integrins αvβ3 and α6β1. Lastly, the increased TF expression in tumors is associated with the release in blood of TF-positive procoagulant microparticles that favor thromboembolic complications. Therefore, the interruption of asTF and flTF signaling represents a potential antiangiogenic strategy. In this review, we summarize the current knowledge on the role of TF in cancer, and we explore therapeutic perspectives based on TF targeting.


Articles with similar content:

Role of the D Prostanoid Receptor 1 in the Modulation of Immune and Inflammatory Responses
Critical Reviews™ in Immunology, Vol.24, 2004, issue 5
Christelle Faveeuw, Philippe Gosset, Veronique Angeli, Francois Trottein
Role of cAMP Phosphodiesterase 4 in Regulation of T-Cell Function
Critical Reviews™ in Immunology, Vol.26, 2006, issue 5
Kjetil Tasken, Elisa Bjorgo
Coactivation and Corepression in Transcriptional Regulation by Steroid/Nuclear Hormone Receptors
Critical Reviews™ in Eukaryotic Gene Expression, Vol.8, 1998, issue 2
J. Don Chen, Hui Li
Hdac-Mediated Control of Endochondral and Intramembranous Ossification
Critical Reviews™ in Eukaryotic Gene Expression, Vol.21, 2011, issue 2
Meghan E. McGee-Lawrence, Elizabeth W. Bradley, Jennifer J. Westendorf
Function of Histone Deacetylase Inhibitors in Inflammation
Critical Reviews™ in Immunology, Vol.31, 2011, issue 3
Paul P. Tak, Kris A. Reedquist, Aleksander M. Grabiec